Tagged with

Hong Kong Novartis Hong Kong general manager Dorine Leung and oncology head Sian Ng discuss the company’s restructuring, dividing the oncology business unit from the pharmaceutical division. In addition, they share their insights on what makes Hong Kong a destination for world-class clinical trials. Novartis recently underwent a major restructuring with the…

Austria Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct Austrian operations. Furthermore, he provides an insight into the peculiarities of market access within Austria compared to other European nations…

Colombia Luz Stella Gomez, General Manager for the Colombian medical device distributor Gemedco, talks about the positive impact that INVIMA’s regulations have had on the Colombian health sector, Gemedco’s portfolio evolution since General Electric’s acquisition, upcoming partnerships for 2017 and the company’s focus on bringing value to the market. Ms. Gomez,…

Austria Eva Bano, CEO of BANO, an exciting west Austrian company, discusses the company’s modern revamp and expansion from natural therapies to pharmaceutical products. She also explains the importance of a strong online presence, the opening of a new production plant and the distribution services they offer for potential partners within…

Austria Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the services and one stop shop approach they provide for their three main focuses; Big Pharma, small to mid-size biotechs and…

Ukraine Tetiana Korotchenko, Country Representative of Crown Agents, one of the three international organizations contracted by the Ukrainian government to temporarily handle healthcare procurement and put an end to the plague of corruption that has engulfed the country, provides insights into the obstacles faced while establishing this crucial program and the…

Austria Michael Krebs, managing director of the Institute of Molecular Biotechnology (IMBA), the leading publicly funded non-university biomedical research organization in Austria, provides an overview of IMBA’s role in the Austrian biomedical ecosystem. Furthermore, he gives an insight into Austria compared to the rest of Europe and delivers exciting news on…

USA Janet Lynch Lambert, CEO of the Alliance for Regenerative Medicine (ARM), discusses the association’s aims and membership, the importance of creating a supportive reimbursement environment for regenerative medicine, and the huge and expanding need for education in this critical area. What was the initial inspiration behind setting up the Alliance…

Austria Christina Nageler, managing director of the Austrian Self Care Association (IGEPHA), the representative voice of the Austrian OTC community, provides an insight into the obstacles associated with the sale of OTC products and the change required in the Austrian mentality towards self-care. Furthermore, she highlights how an effective OTC system…

Austria Wolfgang Jank, general manager and founder, and Tina Theuer, managing partner, of first pharma J.M.T. GmbH, a young Austrian pharmaceutical service company, discuss the challenges of founding a new business and the obstacles companies face when launching products in Austria. They also provide an in-depth analysis of the services they…

Colombia Adriana Forero, General Manager of GSK Colombia, speaks about their efforts to remain at the forefront of the healthcare industry, while keeping their focus on increasing access, innovation and focus on the patient in order to become a strategic partner for the Government and the Colombian healthcare system Ms. Forero,…

Austria Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well as providing an overview of the soon to be completed 700 million EUR biopharmaceutical production plant to be built in…